Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Parkinson's Disease

Free Subscription Articles published in Exp Neurol Retrieve available abstracts of 56 articles: HTML format

Single Articles

July 2024
1. SAGREDO GT, Tanglay O, Shahdadpuri S, Fu Y, et al
   ?-Synuclein levels in Parkinson's disease - Cell types and forms that contribute to pathogenesis.
   Exp Neurol. 2024;379:114887.
   PubMed     Abstract available
   
   
   June 2024
2. KASANGA EA, Soto I, Centner A, McManus R, et al
   Moderate intensity aerobic exercise alleviates motor deficits in 6-OHDA lesioned rats and reduces serum levels of biomarkers of Parkinson's disease severity without recovery of striatal dopamine or tyrosine hydroxylase.
   Exp Neurol. 2024;379:114875.
   PubMed     Abstract available
   
   
   
3. LEI J, Tang LL, Jing R, You HJ, et al
   Antinociceptive role of the thalamic dopamine D3 receptor in descending modulation of intramuscular formalin-induced muscle nociception in a rat model of Parkinson's disease.
   Exp Neurol. 2024 Jun 13:114846. doi: 10.1016/j.expneurol.2024.114846.
   PubMed     Abstract available
   
   
   April 2024
4. FERREIRA AFF, Ulrich H, Feng ZP, Sun HS, et al
   Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model.
   Exp Neurol. 2024;377:114780.
   PubMed     Abstract available
   
   
   March 2024
5. RUNWAL GM, Edwards RH
   The role of alpha-synuclein in exocytosis.
   Exp Neurol. 2024;373:114668.
   PubMed     Abstract available
   
   
   February 2024
6. JACQUES WJ, Estelle M, Samuel G, Belkacem M, et al
   State-dependent alteration of respiration in a rat model of Parkinson's disease.
   Exp Neurol. 2024 Feb 21:114740. doi: 10.1016/j.expneurol.2024.114740.
   PubMed     Abstract available
   
   
   
7. FU X, Qu L, Xu H, Xie J, et al
   Ndfip1 protected dopaminergic neurons via regulating mitochondrial function and ferroptosis in Parkinson's disease.
   Exp Neurol. 2024;375:114724.
   PubMed     Abstract available
   
   
   January 2024
8. MAZZOCCO MT, Serra M, Maspero M, Coliva A, et al
   Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease.
   Exp Neurol. 2024 Jan 26:114704. doi: 10.1016/j.expneurol.2024.114704.
   PubMed     Abstract available
   
   
   
9. DAADI EW, Daadi ES, Oh T, Li M, et al
   Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets.
   Exp Neurol. 2024 Jan 23:114694. doi: 10.1016/j.expneurol.2024.114694.
   PubMed     Abstract available
   
   
   
10. SEILER JL, Zhuang X, Nelson AB, Lerner TN, et al
    Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.
    Exp Neurol. 2024;374:114693.
    PubMed     Abstract available
    
    
    
11. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    Insights into neuroinflammatory mechanisms of deep brain stimulation in Parkinson's disease.
    Exp Neurol. 2024 Jan 8:114684. doi: 10.1016/j.expneurol.2024.114684.
    PubMed     Abstract available
    
    
    December 2023
12. CORSI S, Scheggi S, Pardu A, Braccagni G, et al
    Corrigendum to "Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease" [Experimental neurology 2023 May;363:114370].
    Exp Neurol. 2023 Dec 15:114640. doi: 10.1016/j.expneurol.2023.114640.
    PubMed    
    
    
    
13. MANCHINU MF, Pala M, Palmas MF, Diana MA, et al
    Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study.
    Exp Neurol. 2023 Dec 11:114651. doi: 10.1016/j.expneurol.2023.114651.
    PubMed     Abstract available
    
    
    
14. RADEMACHER K, Nakamura K
    Role of dopamine neuron activity in Parkinson's disease pathophysiology.
    Exp Neurol. 2023 Dec 11:114645. doi: 10.1016/j.expneurol.2023.114645.
    PubMed     Abstract available
    
    
    
15. ESER P, Kocabicak E, Bekar A, Temel Y, et al
    The interplay between neuroinflammatory pathways and Parkinson's disease.
    Exp Neurol. 2023 Dec 5:114644. doi: 10.1016/j.expneurol.2023.114644.
    PubMed     Abstract available
    
    
    
16. NIU B, Zhao M, Gao X, Xu J, et al
    TMT-based quantitative proteomics analysis of neuroprotective effects of Forsythoside A on the MPTP-induced Parkinson's disease mouse model.
    Exp Neurol. 2023 Dec 4:114642. doi: 10.1016/j.expneurol.2023.114642.
    PubMed     Abstract available
    
    
    November 2023
17. XIAO Z, Wang X, Pan X, Xie J, et al
    Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
    Exp Neurol. 2023;372:114614.
    PubMed     Abstract available
    
    
    October 2023
18. BARCOMB K, Ford CP
    Alterations in neurotransmitter co-release in Parkinson's disease.
    Exp Neurol. 2023;370:114562.
    PubMed     Abstract available
    
    
    August 2023
19. KASANGA EA, Han Y, Shifflet MK, Navarrete W, et al
    Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs.
    Exp Neurol. 2023;368:114509.
    PubMed     Abstract available
    
    
    
20. KASANGA EA, Han Y, Navarrete W, McManus R, et al
    Differential expression of RET and GDNF family receptor, GFR-alpha1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling.
    Exp Neurol. 2023;366:114435.
    PubMed     Abstract available
    
    
    June 2023
21. LIU Y, Liu H, Lu Y, Yin X, et al
    Non-invasive auditory and visual stimulation attenuates alpha-Synuclein deposition and improves motor and non-motor symptoms in PD mice.
    Exp Neurol. 2023;364:114396.
    PubMed     Abstract available
    
    
    May 2023
22. HART M, Conrad J, Barrett E, Legg K, et al
    X-linked hydrocephalus genes: Their proximity to telomeres and high a + T content compared to Parkinson's disease.
    Exp Neurol. 2023 May 6:114433. doi: 10.1016/j.expneurol.2023.114433.
    PubMed     Abstract available
    
    
    April 2023
23. RIVAS-SANTISTEBAN R, Lillo J, Raich I, Munoz A, et al
    The cannabinoid CB(1) receptor interacts with the angiotensin AT(2) receptor. Overexpression of AT(2)-CB(1) receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats.
    Exp Neurol. 2023;362:114319.
    PubMed     Abstract available
    
    
    March 2023
24. SARA C, Simona S, Alessandra P, Giulia B, et al
    Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Exp Neurol. 2023 Mar 4:114370. doi: 10.1016/j.expneurol.2023.114370.
    PubMed     Abstract available
    
    
    January 2023
25. PETERSON V, Merk T, Bush A, Nikulin V, et al
    Movement decoding using spatio-spectral features of cortical and subcortical local field potentials.
    Exp Neurol. 2023;359:114261.
    PubMed     Abstract available
    
    
    December 2022
26. THOMSEN M, Stoica A, Christensen KV, Fryland T, et al
    Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
    Exp Neurol. 2022;358:114209.
    PubMed     Abstract available
    
    
    October 2022
27. LAI HJ, Deng CR, Wang RW, Lee LN, et al
    The genesis and functional consequences of cortico-subthalamic beta augmentation and excessive subthalamic burst discharges after dopaminergic deprivation.
    Exp Neurol. 2022;356:114153.
    PubMed     Abstract available
    
    
    August 2022
28. DE LUZY IR, Pavan C, Moriarty N, Hunt CPJ, et al
    Identifying the optimal developmental age of human pluripotent stem cell-derived midbrain dopaminergic progenitors for transplantation in a rodent model of Parkinson's disease.
    Exp Neurol. 2022 Aug 30:114219. doi: 10.1016/j.expneurol.2022.114219.
    PubMed     Abstract available
    
    
    
29. MEIER JM, Perdikis D, Blickensdorfer A, Stefanovski L, et al
    Virtual deep brain stimulation: Multiscale co-simulation of a spiking basal ganglia model and a whole-brain mean-field model with The Virtual Brain.
    Exp Neurol. 2022;354:114111.
    PubMed     Abstract available
    
    
    June 2022
30. BELOVA ECAPITAL EM, CYRILLIC, Filyushkina VI, Dzhalagoniia I, Gamaleya AA, et al
    Oscillations of pause-burst neurons in the STN correlate with the severity of motor signs in Parkinson's disease.
    Exp Neurol. 2022 Jun 27:114155. doi: 10.1016/j.expneurol.2022.114155.
    PubMed     Abstract available
    
    
    
31. DARCY N, Lofredi R, Al-Fatly B, Neumann WJ, et al
    Spectral and spatial distribution of subthalamic beta peak activity in Parkinson's disease patients.
    Exp Neurol. 2022 Jun 19:114150. doi: 10.1016/j.expneurol.2022.114150.
    PubMed     Abstract available
    
    
    
32. HUSSEIN A, Tielemans A, Baxter MG, Benson DL, et al
    Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson's disease Lrrk2(G2019S) knockin mutation.
    Exp Neurol. 2022 Jun 19:114145. doi: 10.1016/j.expneurol.2022.114145.
    PubMed     Abstract available
    
    
    
33. RAUSCHENBERGER L, Guttler C, Volkmann J, Kuhn A, et al
    A translational perspective on pathophysiological changes of oscillatory activity in dystonia and parkinsonism.
    Exp Neurol. 2022 Jun 8:114140. doi: 10.1016/j.expneurol.2022.114140.
    PubMed     Abstract available
    
    
    May 2022
34. WIEST C, Torrecillos F, Tinkhauser G, Pogosyan A, et al
    Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia.
    Exp Neurol. 2022;351:113999.
    PubMed     Abstract available
    
    
    April 2022
35. PARR-BROWNLIE LC, Itoga CA, Walters JR, Underwood CF, et al
    Oscillatory waveform sharpness asymmetry changes in motor thalamus and motor cortex in a rat model of Parkinson's disease.
    Exp Neurol. 2022 Apr 21:114089. doi: 10.1016/j.expneurol.2022.114089.
    PubMed     Abstract available
    
    
    March 2022
36. PEREIRA MCL, Boese AC, Murad R, Yin J, et al
    Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
    Exp Neurol. 2022 Mar 7:114042. doi: 10.1016/j.expneurol.2022.114042.
    PubMed     Abstract available
    
    
    February 2022
37. WENGER N, Vogt A, Skrobot M, Garulli EL, et al
    Rodent models for gait network disorders in Parkinson's disease - a translational perspective.
    Exp Neurol. 2022 Feb 14:114011. doi: 10.1016/j.expneurol.2022.114011.
    PubMed     Abstract available
    
    
    
38. PENG Y, Schoneberg N, Esposito MS, Geiger JRP, et al
    Current approaches to characterize micro- and macroscale circuit mechanisms of Parkinson's disease in rodent models.
    Exp Neurol. 2022;351:114008.
    PubMed     Abstract available
    
    
    January 2022
39. MIZRAHI-KLIGER AD, Feldmann LK, Kuhn AA, Bergman H, et al
    Etiologies of insomnia in Parkinson's disease - Lessons from human studies and animal models.
    Exp Neurol. 2022;350:113976.
    PubMed     Abstract available
    
    
    
40. BUSCH JL, Feldmann LK, Kuhn AA, Rosenblum M, et al
    Real-time phase and amplitude estimation of neurophysiological signals exploiting a non-resonant oscillator.
    Exp Neurol. 2022;347:113869.
    PubMed     Abstract available
    
    
    November 2021
41. OH T, Daadi ES, Kim J, Daadi EW, et al
    Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
    Exp Neurol. 2021;347:113920.
    PubMed     Abstract available
    
    
    October 2021
42. MA J, Sun W, Chen S, Wang Z, et al
    The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression.
    Exp Neurol. 2021;347:113904.
    PubMed     Abstract available
    
    
    September 2021
43. CHATURVEDI RK, Shukla S, Seth K, Agrawal AK, et al
    Corrigendum to "Zuckerkandl's organ improves long-term survival and function of neural stem cell's derived dopaminergic neurons in parkinsonian rats" [Experimental Neurology Volume 210, Issue 2, April 2008, Pages 608-623].
    Exp Neurol. 2021 Sep 11:113859. doi: 10.1016/j.expneurol.2021.113859.
    PubMed    
    
    
    
44. YEH TH, Liu HF, Chiu CC, Cheng ML, et al
    PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia-parkinsonism type 14 and can be relieved by DHA treatment in animal models.
    Exp Neurol. 2021 Sep 11:113863. doi: 10.1016/j.expneurol.2021.113863.
    PubMed     Abstract available
    
    
    July 2021
45. LEE JE, Kim HN, Kim DY, Shin YJ, et al
    Memantine exerts neuroprotective effects by modulating alpha-synuclein transmission in a parkinsonian model.
    Exp Neurol. 2021 Jul 13:113810. doi: 10.1016/j.expneurol.2021.113810.
    PubMed     Abstract available
    
    
    June 2021
46. LAPPIN JM, Darke S
    Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review.
    Exp Neurol. 2021 Jun 21:113793. doi: 10.1016/j.expneurol.2021.113793.
    PubMed     Abstract available
    
    
    May 2021
47. BINDA KH, Lillethorup TP, Real CC, Baerentzen SL, et al
    Exercise protects synaptic density in a rat model of Parkinson's disease.
    Exp Neurol. 2021;342:113741.
    PubMed     Abstract available
    
    
    
48. LIU Z, Yan A, Zhao J, Yang S, et al
    The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2021;342:113740.
    PubMed     Abstract available
    
    
    April 2021
49. LANGLEY MONICA R, Shivani G, Ay Muhammet PBN, Huajun J, et al
    Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Exp Neurol. 2021 Apr 8:113716. doi: 10.1016/j.expneurol.2021.113716.
    PubMed     Abstract available
    
    
    March 2021
50. BECKSTEAD MJ, Howell RD
    Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Exp Neurol. 2021 Mar 19:113707. doi: 10.1016/j.expneurol.2021.113707.
    PubMed     Abstract available
    
    
    
51. BERGKVIST L, Johnson ME, Mercado G, Steiner JA, et al
    An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
    Exp Neurol. 2021 Mar 13:113693. doi: 10.1016/j.expneurol.2021.113693.
    PubMed     Abstract available
    
    
    January 2021
52. MCKNIGHT I, Hart C, Park IH, Shim JW, et al
    Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
    Exp Neurol. 2021;335:113523.
    PubMed     Abstract available
    
    
    December 2020
53. SIMMNACHER K, Krach F, Schneider Y, Alecu JE, et al
    Unique signatures of stress-induced senescent human astrocytes.
    Exp Neurol. 2020;334:113466.
    PubMed     Abstract available
    
    
    November 2020
54. SI XL, Fang YJ, Li LF, Gu LY, et al
    From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
    Exp Neurol. 2020 Nov 5:113525. doi: 10.1016/j.expneurol.2020.113525.
    PubMed     Abstract available
    
    
    October 2020
55. HAUMESSER JK, Beck MH, Pellegrini F, Kuhn J, et al
    Subthalamic beta oscillations correlate with dopaminergic degeneration in experimental parkinsonism.
    Exp Neurol. 2020;335:113513.
    PubMed     Abstract available
    
    
    
56. SCHNEIDER JS, Marshall CA, Keibel L, Snyder NW, et al
    A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Exp Neurol. 2020;335:113514.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.